Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Extension Study, An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trials to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease

NCT02926300 is registered in ClinicalTrials.gov with Kang Stem Biotech Co., Ltd. as lead sponsor.

NCT NCT02926300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02926300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Extension Study, An Open-labelled, Multi Center, Comparative Phase I/IIa Clinical Trials to Evaluate the Efficacy and Safety of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease
Lead sponsor
Kang Stem Biotech Co., Ltd.
Phase
Observational
Overall status
Unknown status
Start date
November 30, 2015
Completion date
November 30, 2021
Enrollment
24 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease